Overview

A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Status:
Completed

Trial end date:
2018-08-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of ponatinib in Japanese patients with chronic myeloid leukemia (CML) who have experienced failure of dasatinib or nilotinib or with Ph+ acute lymphoblastic leukemia (ALL) following failure of prior tyrosine kinase inhibitors (TKIs).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ariad Pharmaceuticals

Treatments:

Ponatinib